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Trm role of platelet-activating factor (PAF) as a
mediator of increased conjunctival vascular perm-
eability was investigated in a guinea-pig model of
immediate hypersensitivity. Vascular permeability
of the conjunctiva was determined by measuring
the albumin content in lavage fluid (IF) after
topical challenge with either PAF or ovalbumin.
PAF produced a dose-dependent increase of the
vascular permeabilitywithin minutes. Topical pre-
treatment with levocabastine, a potent histamine
HI-antagonist demonstrated no effect towards the
vascular permeability in response to PAF provoca-
tion. Pretreatment with eyedrops containing the
specific PAF antagonist BN 52021 (1%) showed a
significant inhibition of the vascular permeability
(60.2%) and the clinical score (27.5%) after PAF
challenge. In sensitized guinea-pigs, levocabastine
showed a marked inhibition of both the vascular
permeability (80.5%) and the clinical score (70%)
after topical challenge with ovalbumin. BN 2021,
although to a lesser extent, showed a similar effect
towards the vascular permeability (26.8%) and the
clinical score (28%) after antigen provocation.
When BN 52021 and levocabastine were admin-
istered in combination, the vascular permeability
was significantly decreased after antigen challenge
in comparison with eyes pretreated with levoca-
bastine alone. These results indicate that PAF plays
a role in the acute phase of allergic conjunctivitis
in the guinea-pig.
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Introduction
Allergic conjunctivitis is characterized by bilat-
eral hyperaemia, itching, tearing and oedema.
Increased vascular permeability has also been
described as an important feature of allergic con-
junctivitis. It is an immediate hypersensitivity
reaction (type I); after interaction of the antigen-
IgE antibody complex with the mast cell, the clin-
ical signs and symptoms appear within minutes.
Histamine, released from the granules of the mast
cell, seems to play a key role but other mediators
including leukotrienes (LT), prostaglandins (PG)
and platelet-activating factor (PAF) seem to take
part in the inflammatory process.
2
PAF has been shown to induce a wide variety
of biological actions such as chemotaxis and
activation of neutrophils and eosinophils;
4
moreover PAF induces increased vascular perme-
ability.5 On a molar basis, PAF appeared to be
1 000 to 10000 times more potent in inducing
vascular permeability changes in skin compared
with histamine.
6 Because of these effects, PAF
has been implicated in the pathogenesis of aller-
(C) 1995 Rapid Communications of Oxford Ltd
gic diseases including allergic conjunctivitis.
In a number of studies PAF receptor antagon-
ists have been shown to be very effective in inhi-
biting various effects after PAF challenge in
different models. In the eye, PAF antagonists
have been shown to be capable of inhibiting
corneal oedema formation and pupillar constric-
tion after intracameral injection of PAF’ and they
partially reduced the endotoxin-induced break-
down of the blood-aqueous barrier.
8 Further-
more, the specific PAF antagonist BN 52021
showed a significant inhibition of oedema, leuco-
cyte infiltration and vascularization of the cornea
in a rabbit model of immunogenic keratitis9 after
challenge with albumin. In view of these findings,
we studied the inhibitory effect of BN 52021
towards microvascular permeability and clinical
signs after PAF and antigen provocation in a
guinea-pig model of immediate hypersensitivity.
Materials and Methods
Female Hartley strain guinea-pigs (weight
range, 350-450 g) were sensitized to ovalbumin
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housed and cared in accordance with the guide-
lines of the ARVO statement for the use of
animals in ophthalmic and vision research.
Clinical score: For estimation of the inflammatory
signs, the total impression of hyperaemia,
oedema and swelling was combined in a clinical
score (CS) and expressed by visual analogic
scales 0-100% by two independent observers.
Albumin assay: Total albumin concentration in
LF was determined using radial immunodiffusion.
Samples were tested in an appropriate dilution.
Agar plates (1.5%) containing a 1/100 dilution of
guinea-pig albumin anti-serum were used for this
purpose. Various concentrations of guinea-pig
0 00 albumin were used as a standard.
Dose PAF (lg)
FIG. 1. Dose response curve for PAF on albumin recovery in LF
after 30 rain. (n 3).
Statistical evaluation: Student’s t-test was used
for statistical calculations. A p value < 0.01 was
taken as significant.
by i.p. injection of a mixture containing 10 l-tg Results ovalbumin and 0.1 g aluminium hydroxide sus-
pended in 0.5 ml saline. Two to 3 weeks later, Effects ofPAE.. Topical application of PAF (10 l.tg)
ovalbumin (0.5%) or PAF (10 l.tg) were applied resulted, within 5 min, in an inflammatory reac-
topically in 25 1 eye drops. Ovalbumin eye tion consisting of hyperaemia, conjunctival
drops were prepared as a 0.5% solution in phos- oedema and periorbital swelling which dis-
phate buffered saline (PBS). Preliminary experi- appeared within 4h. The maximum CS was
ments (not reported here) had shown that this observed after 30 min.
dose of ovalbumin produced a useful response PAF provocation produced a dose related
in terms of clinical signs and microvascular per- increase of the albumin concentration in LF (Fig.
meability. 1). The minimal dose to provoke a leakage of
PAF (C18) was dissolved in water and stored at albumin from the conjunctiva vessels was 3 I.tg/
4C according to the manufacturer’s instructions, eye. Maximum levels of albumin in LF were
Just prior to the performance of the experiment, found after 30 min, showing a decline to zero 4 h
the stock solution was further diluted in PBS, after challenge (Fig. 2). The increase of the vas-
using polypropylene tubes and pipette tips. cular permeability with time showed a straight
BN 52021 (1%) or levocabastine (0.05%) were correlation with the development of clinical signs
dissolved in 0.3% hypromellose and applied at and symptoms.
random to one eye l h before challenge with Pretreatment with BN 52021 showed a sig-
PAF or antigen. The contralateral eye served as a nificant effect on both the CS (Fig. 3) and the
control and received the solvent, albumin concentration in LF (Fig. 4). The mean
Clinical score (CS) was determined and albumin content in LF after BN 52021 treatment
lavage fluid (LF) was collected at 0.5, 1, 2 and was inhibited (by 60.2%) in comparison with
4h. LF was sampled by washing the eye with control eyes.
PBS (25 btl) using a polypropylene micropipette, Levocabastine showed no effect on the CS and
avoiding touching the eye. After three forced failed to reduce the conjunctival microvascular
blinks the LF was collected and stored at-20C permeability after PAF administration.
until used.
Ovalbumin was purchased from Sigma (St Effects of ovalbumin: Ovalbumin administration
Louis, MO), PAF from Cayman (Ann Arbor, MI), produced a dose-dependent increase in vascular
guinea-pig albumin anti-serum and guinea-pig permeability in sensitized animals (data not
albumin from Nordic (Tilburg, the Netherlands). shown). As a useful concentration for our
BN 52021 was donated by the institute Henri experiments, a 0.5% solution of ovalbumin was
Beaufour (Le Plessis Robinson, France) and levo- used .(dose per eye 125 l.tg). The inflammatory
cabastine hydrochloride was a gift from Janssen response to ovalbumin showed a similar clinical
pharmaceutics (Beerse, Belgium). Animals were reaction in comparison with PAF. After 24 h the
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FIG. 2. Time course for albumin recovery in LF in response to
PAF (10 g/eye) and ovalbumin (250 lg/eye) after 30 min (n
8). PAF, ((C)); ovalbumin, (O).
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FIG. 3. Effect of levocabastine 0.05% (Levo) and BN 52021 1%
(BN) on the clinical score in response to PAF provocation (10
Ig/eye) after 30 min (n 8).
*Significant difference from eyes receiving only the solvent
(control) p < 0.01.
eyes of the challenged guinea-pigs were free
from signs of inflammation.
Levocabastine as a pretreatment significantly
reduced the mean of the clinical score (Fig. 5)
and showed a significant inhibition (80.5%) of
the vascular permeability (Fig. 6). BN 52021
alone showed a significant effect towards the
inflammatory response after ovalbumin challenge,
reducing the clinical score and inhibiting the
vascular permeability (26.8%). The combination
of levocabastine (0.05%) and BN 52021 (1%) in
one solution showed an even greater inhibitory
effect towards the clinical score and vascular
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FIG. 4. Effect of levocabastine 0.05% (Levo) and BN 52021 1%
(BN) on albumin recovery in LF in response to PAF provocation
(10 lg/eye) after 30 min (n 8).
*Significant difference from eyes receiving only the solvent
(control) p < 0.01.
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FIG. 5. Effect of levocabastine 0.05% (Levo), BN 52021 1% (BN)
and a combination of both (Levo + BN) on the clinical score in
response to ovalbumin provocation (125 #g/eye) after 30 min
(n 5-8).
*Significant difference from eyes receiving only the solvent
(control) p < 0.01
VSignificant difference from eyes receiving levocabastine (Levo)
p< 0.01.
permeability (Figs. 5 and 6) in comparison with
levocabastine alone. The mixture showed a sig-
nifican inhibition of the mean clinical score
(73%) and the vascular permeability (79%), as
compared with the effect of levocabastine alone.
Discussion
This study shows that PAF plays a role in the
acute phase of allergic conjunctivitis. Topical
application of PAF to the eyes of guinea-pigs
resulted in an inflammatory response including
hyperaemia, oedema and swelling of the con-
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allergic conjunctivitis. However, a substantial part
a00- of the inflammatory response remains present -
using histamine antagonists as a pretreatment,
reflecting the possible involvement of other med-
s0- :.:.:.:.:.:.:.:.:.:.:.:.:..:.:.::.iiiiiiii{iiiiiiii{iiiiiiiiiiiiiiiii iators. Our study shows that pretreatment with
iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii BN 52021 alone and in combination with levoca- -
a00 iii{iiiiiiiiiiiiiiiiiiiiiiiiii{iiiiiill bastine before antigen challenge resulted in a
iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiil iiiiiiiiiiiiiiiii significant inhibition of the clinical score and vas- ._ s0 iiiiiiiiiiiiiiiiii!iiiiiiiiiiiiii iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii cular permeability (Figs. 5 and 6) This suggests
= iiiiiiiiiiiiiiiiiii{iiiiiiiiiii{ii iiiiiiii{iiiiiiiiiiiii{{iiiii{ii{i that the non-histaminergic component of the
,00 iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiil ii!iiiiiiiiiiiiiiiiiiiiiii!iiiiiii acute phase of allergic conjunctivitis is at least
Z .... ..!!..!!...... .....!! ::::::::::=:ii::iii::iiiii{i::iiiiii:=iiiii:: iii{iiiiiiiiiiiiiiiii{i}ii}iiiiiii iiii{i!iiii!{!i{iii{iiiiiiiii{iiii partly mediated by PAF. Other reports also
so !i!ii!iii!!iiiiiiiiiiiiiiii{iiiil iii!iiii{ii{iii{iii{!ii{!i{ii{iii! showed a significant effect of different PAF
iiiiii{i!!iiiii!ii!iiii!!i!i{iiiiiiiii iiiii!ili!i!iiiiiiii{iiiiiii!iiiiiiiii!i antagonists on the vascular permeability in
Gontrol {_evo IBN I_evo + BN The mechanism of action of PAF is still not
FIG. 6. Effect of levocabastine O.OB% (kvo), BN 2021 1% (BN) completely understood. PAF receptors situated
and a combination of both (l_vo + BN) on the albumin reovery on target cells are thought to be responsible for
in I_F in rspons to ovalbumin halln {12S t/ye} after 30 the effects of PAF.
8 But it has also been sug-
rain (n= -8). gested that PAF employs its activity via the sec- *Significant diffrn from es reivin only th solvent
{control) # < 0.01. ondary synthesis of lipoxygenase products.9 It is
"Significant differen from m/s receiving levoeabastine (l_vo) likely that many of the effects attributed to PAF
< 0.O1. are dependent on the secondary generation of
LT and PG. PAF has been shown to release LT,
2
junctiva. Moreover, PAF provocation showed a and in a rabbit conjunctival provocation model
dose dependent increase in conjunctival vascular the inflammatory response after PAF challenge
permeability. Our results coincide with the could be inhibited using a lipoxygenase inhib-
observations of others who applied PAF to the itor.
2 Also, topical administration of LT results in
10 11 12 eyes of rats and guinea-pigs. The dose of a similar inflammatory response when compared
PAF needed to produce an inflammatory with PAF provocation.
22 However, LT antagonists
response of the conjunctiva seems very high appeared to be less effective in suppressing the
when compared with the dose of PAF, less than conjunctival vascular permeability after antigen
0.1 l-tg, used in other models. In a rabbit model administration in comparison with exogenous
of ocular hypertension, a dose of 250 tg per eye LT challenge in guinea-pigs. Because of the
in the presence of 0.25% HSA was topically, significant effect of BN 52021 after ovalbumin
administered without any systemic side effects. challenge, it seems that PAF plays a more promi-
This may be explained by the unique character- nent role compared to LT in the acute phase of
istics of the eye towards topical administration of allergic conjunctivitis in guinea-pigs.
PAF. (Possibly PAF is rapidly converted to lyso- Because levocabastine pretreatment showed
PAF by enzymatic hydrolysis or PAF does not no effect on CS and vascular permeability after
easily penetrate the outer surface of the eye). PAF administration, it seems that PAF does not
Because albumin levels in LF and the CS both trigger the mast cell to release histamine from its
reached a maximum after 30 min, we selected granules. This is confirmed by the observation
this as a time point to test the effectiveness of that during in vitro experiments PAF was not
the specific PAF antagonist BN 52021 and the H1- able to release histamine from human dispersed
antagonist levocabastine after provocation with cutaneous mast cells.23
antigen or PAF. Because albumin is not produced by the lacri-
Pretreatment with levocabastine reduced the mal gland of the guinea-pig,
24 the concentration
inflammatory response after topical administra- of albumin on the ocular surface of the eye is a
tion to antigen to sensitized guinea-pigs for the result of the flow of tissue fluids and other
major part (Figs. 5 and 6). Woodward et al. 15 serum proteins across the epithelium to the
observed a similar effect using a combination of ocular surface under the influence of several
H1 and H2-antagonists in guinea-pigs, and in a mediators. The LF collected from the surface of
human study levocabastine appeared to be very the eye at this stage is a mixture of ’leaking’
effective in relieving the clinical signs and symp- serum and reflex tearing from the lacrimal gland,
toms when used by patients with allergic con- resulting in some variation between animals but
junctivitis.
16 These observations indicate the not between the eyes of one animal. Stock et
dominant role of histamine in the acute phase of al. observed that in the conjunctival system the
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clinical evaluation was as good as an experi-
mental estimate of the mediator effect measured
by extravasation of Evans blue. Because, in our
model, clinical score and albumin leakage
showed a clear correlation, the observed differ-
ences in albumin leakage are due to pharmacolo-
gical effects and not to the collection method of
the LF.
Although the major response in the immediate
hypersensitivity reaction seems to be histamine
mediated, the effectiveness of BN 52021 in inhib-
iting the inflammatory response after ovalbumin
challenge demonstrates the important role of
PAF in the acute phase of allergic conjunctivitis.
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